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Abstract
Background: Anxiety disorders occur commonly in schizophrenia but are often overlooked by psychiatrists. Their presence 
may compound the challenges faced by these patients and may contribute to poor outcome.
Objectives: The purpose of  this study was to determine the prevalence of  anxiety disorders among the participants with 
schizophrenia, and the association between this co-morbidity and disability.
Method: A total of  367 participants were recruited from the out-patient department of  Federal neuropsychiatric hospital 
Enugu, Nigeria.  Socio-demographic  questionnaire,  schedules  for clinical assessment in neuropsychiatry, positive and neg-
ative syndrome scale and the 12-item  version  of   the  World  Health  Organization  disability  assessment   schedule  were 
administered. 
Results:  A total of   189 females (51.5%)  and 178 (48.5%)  males were  studied. A lifetime prevalence of  12.3% was re-
ported for anxiety disorder. Anxiety disorder was more likely in females (κ²=4.93, p<0.03). Specific  prevalence  for  anxiety 
disorder  in  schizophrenia  was generalized  anxiety  disorder 6.3%,  obsessive  compulsive  disorder 3.3%, and  phobic 
anxiety  disorder 2.7%. Anxiety disorder was associated with increased disability (t=3.50, p<0.001) and psychopathology 
(t=3.40, p<0.001) among the participants studied. Phobias were associated with prescription of  low doses of  antipsychotics 
(κ²=4.08, p<0.04). There was a low rate of  identification of  anxiety disorder in routine clinical practice (k=0.08, p<0.001).
Conclusion: Co-morbid anxiety disorders are common in schizophrenia and they are associated with increased disability 
and psychopathology. The results emphasize the need to screen for anxiety disorders in patients with schizophrenia.
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Introduction
Anxiety disorder is a blanket term covering several dif-
ferent forms of  abnormal and pathological fears and 
anxieties1. There are several forms of  anxiety disorders 
which include generalized anxiety disorder, panic disor-
der, phobias and obsessive compulsive disorder2. Anx-
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For over a hundred years now, clinicians and researchers 
have been challenged by the co- occurrence  of   anxiety 
symptoms and psychotic  illness4. Early clinicians, such 
as Westphal, Kraepelin, Stengel, and Bleuler considered 
it either a prodrome or an integral part of  the schizo-
phrenic illness5. 
 
Many studies show that Anxiety disorders co-occur 
commonly in schizophrenia6. Review of  literature has 
reported a wide range of  prevalence for anxiety disor-
der in schizophrenia ranging from 30-85%7. A study 
carried out in Brazil reported that at least 51% of  pa-
tients with schizophrenia met criteria for at least one 
form of  anxiety disorder6. In Turkey, a study that re-
cruited  82  out-patients  with  schizophrenia  diagnosed 
fifty-five  (67.1%)  with  at  least  one lifetime co-morbid 
anxiety disorder8. A work that studied racial disparity in 
the rate of  diagnosis of  anxiety disorder in Caucasians 
and African-Americans reported an anxiety disorder di-
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agnosis rate of  27% in Caucasians and 13% in African 
Americans.9
A study which was part of  Nigerian survey of  mental 
health and wellbeing conducted in 8 out of  the 22 states 
in Nigeria, thus representing about 22% of  the national 
population reported that persons  with  psychotic  ex-
periences  were  more  likely to  have  experienced  other 
co-morbid disorders  like mood disorders, anxiety dis-
orders, substance use disorders10. The same study re-
ported a 15% co-morbidity rate for anxiety disorders in 
patients with non-affective psychosis (including schizo-
phrenia and schizophreniform disorders)10.
A Turkish study reported the most common anxiety 
disorder to be obsessive compulsive disorder (39.0%), 
followed by social phobia with a prevalence rate of  
13.4%8. Other studies reported specific  prevalence  of  
social  phobia  (17%),  obsessive  compulsive  disorder  
(15.1%), generalized anxiety disorder (9.4%), panic dis-
order (5.7%), specific  phobia (5.7%) and 1.9%   for 
agoraphobia11.  A large   community-based, controlled, 
prospective study in   in newly diagnosed patients with 
psychotic disorders found 10 to 20 - percent prevalence 
rates for co-morbid  obsessive compulsive disorder12. 
 
While anxiety disorder is common in schizophrenia, it 
is not clear if  it affects functioning. Reports about the 
effects of  co-morbid anxiety disorder on function have 
varied with some studies reporting greater functional 
impairment5 while others found no significant differ-
ence between the two comparison groups13.  Rosen and 
Jahreiss in 1946 concluded that the presence of  obses-
sive compulsive symptoms  conferred some  protection 
against  cognitive  deficits, functional impairment, and 
negative symptoms associated with schizophrenia14. 
However, more recent studies that used rigorous meth-
ods have not replicated these earlier findings15 but rath-
er have shown poorer outcome5 and a severe level of  
disability16,17. It has also being associated with a great 
deal of  suffering with increase in hopelessness, suicide 
risk, higher rates of  relapse, re-hospitalization18 and 
poorer social functioning16. A study conducted in Nige-
ria reported low quality of  life in patients with schizo-
phrenia who had co-morbid anxiety disorder19. A study 
carried  out  in  Israel  in  2009  by  Mazeh  et  al  report-
ed  higher  total  positive  and  negative syndrome scale 
(PANSS) score in in-patients with co-morbid anxiety in 
schizophrenia but this did not reach statistical signifi-
cance20. A high positive correlation was also reported 
between the severity of  anxiety symptoms and positive 
symptoms in schizophrenia21.
However some studies have found patients with a di-
agnosis of  schizophrenia with co-morbid anxiety dis-
order to have a shorter duration of  illness compared 
to those without such co-morbid condition8. Another 
study by Lysaker et al among patients with obsessive 
compulsive symptoms found no correlation between 
the presence of  anxiety symptoms and the severity of  
positive psychotic symptoms in schizophrenia22. Ems-
ley in 2001 proposed that anxiety was a core symptom 
of  schizophrenia and that high level of  anxiety could 
possibly predict a favorable outcome in the treatment 
of  schizophrenia, particularly if  depressive symptoms 
are experienced during the acute phase of  the schizo-
phrenic episode21.
Anxiety disorder in schizophrenia remains largely un-
recognized by clinicians. A study done in Australia on 
100 consecutively admitted in-patients with schizophre-
nia found that anxiety disorders though common (45% 
in the patients studied), was unrecognized by clinicians 
in almost all of  the patients23. Craig, Hwang and Brom-
et reported that only about 10 percent of  patients with 
co-morbid obsessive compulsive symptoms were iden-
tified by the clinicians.
However, despite the low rate of  recognition by cli-
nicians, 20 percent or more of  these patients received 
treatment that was appropriate for co-morbid anxiety 
disorders5.
Few studies have been done to ascertain the clinical im-
plications of  anxiety disorders on patients with schizo-
phrenia in Nigeria. Considering that it is common and 
has been associated with significant disability it becomes 
necessary to study it in this environment.
 
Therefore this study determined
The prevalence of  anxiety disorders among the partic-
ipants with schizophrenia and the association between 





This was a descriptive cross-sectional study carried out 
at Federal neuropsychiatric hospital, Enugu, Nigeria 
between May and December 2011. The sample frame 
consisted of  patients with schizophrenia who attended 
outpatient clinics on Monday, Tuesday, Thursday and 
Friday every week. Patients were selected consecutively 
for the study if  they were being managed at the out-pa-
tient department of  Federal neuropsychiatric hospital 
Enugu, Nigeria if  they had a diagnosis of  schizophre-
nia made by a consultant psychiatrist using ICD-10 cri-
teria and confirmed with present state examination 10 
(PSE), and had no  other  important  physical  condition 
or  mental disorder besides schizophrenia. A total of  
367 patients were recruited.
 
For the participants with a diagnosis of  schizophrenia, 
schizophrenia section of  PSE was administered. Then 
the socio-demographic questionnaire was administered 
to all the participants and/or their accompanying rela-
tives. Information about the participants such as age, 
sex, marital status, level of  education, religious affilia-
tion, occupation, age of  onset of  schizophrenia, use of  
anticholinergic medication and duration of  illness  were 
obtained and coded into a proforma.
Thereafter, anxiety section of  PSE was then adminis-
tered to detect participants with anxiety disorder. Se-
verity of  psychotic symptoms was measured and quan-
tified with PANSS in all participants. Finally World 
Health Organization disability assessment schedule 
(WHODAS) was administered to measure disability in 
all the participants.
After  the  interviews,  from  the  case  notes  of   all 
the  participants  the  following  pieces  of  information 
were extracted: current type and dosage of  antipsychot-
ic medication, and where applicable, more information 
about the patient (socio-demographic data).
Antipsychotic  medications  used  by the  participants 
were  converted  to  their  chlorpromazine equivalents. 
Participants who understood English were interviewed 
with the English language versions of  the study instru-
ments while those who did not understand English 
were administered the  Igbo language  versions by the 
researchers who are  bilingual in both English and Igbo 
languages.
Approval was obtained from the ethics committee of  
the Federal neuropsychiatric hospital Enugu. All partic-
ipants gave voluntary informed consent before recruit-
ment into the study.
Study instruments
1. Socio-demographic Questionnaire:
This instrument was designed to obtain basic infor-
mation about a patient’s health and biodata. Socio-de-
mographic  characteristics  such  as  age,  sex,  marital 
status,  occupation,  employment status, religion, level 
of  education were documented. The age at illness onset 
and illness duration were also recorded.
2. Present State Examination 10 (PSE 10)
This is a structured diagnostic interview schedule that 
has been incorporated into the Schedules for clinical 
assessment in neuropsychiatry (SCAN).
It rates the presence or absence of  symptoms and also 
the severity and frequency of  abnormal beliefs and ex-
periences. The  presence of  each syndrome  can be rat-
ed from case notes and interviews with the respondent 
and his informants.
It confirms the presence of  schizophrenia using at least 
one of  the following first rank symptoms like voices 
commenting or discussing the patient in the third per-
son, loud thoughts, thought insertion,  thought  broad-
cast  or  withdrawal,  delusions  of   control,  delusional 
perception  and bizarre delusions.
Presence of  anxiety is rated on a 2 point scale with 0 in-
dicating that generalized anxiety disorder, panic attacks 
and phobias were ‘absent’ and 1 indicating ‘present’. 
The presences of  obsession and compulsive symptoms 
are also rated on a 2 point scale with 0 indicating no 
evidence of  symptoms and I indicating sufficient evi-
dence to proceed. PSE measures clinical severity by the 
duration and frequency of  symptoms and the degree of  
interference with mental functions (intensity).
Positive and Negative Syndrome Scale (PANSS)
PANSS is a 30-item  questionnaire that is used  to  assess 
patients’  current  mental  state.  It classifies schizophre-
nia into positive and negative subtypes. It has become 
one of  the standard tools for assessing clinical outcome 
in treatment studies of  schizophrenia. The PANSS in-
cludes 30 items on 3 subscales: 7 items covering posi-
tive symptoms, 7 covering negative symptoms and 16 
covering general psychopathology. Each item is scored 
on a seven-point item-specific Likert scale ranging from 
1 to 7; thus the negative and positive subscales each 
range from 7 to 49, and the general psychopathology 
scale from 16 to 112. For the purpose of  this study, 
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scores for the three scales were arrived at by summation 
of  ratings across the component items. The PANSS is 
interviewer administered and reliability for each scale is 
fairly high, with excellent internal consistency and in-
ter-rater reliability.  Validity  also  appears  good  based 
on  correlation  with  other  symptom  severity meas-
ures and factor analytical validation of  subscales.
World Health Organization /Disability Assess-
ment Schedule II (WHODAS) 12 item version
WHODAS is a generic disability measure that is not 
disorder-specific. It was developed in 1988 by World 
Health Organization. It was designed to assess distur-
bance in social adjustment and behavior and the factors 
that might influence these dysfunctions in persons with 
mental illness.
The WHODAS II is a self-report questionnaire that as-
sesses activity limitations and disability in the previous 
month. It was developed to assess six different adult 
life tasks: Understanding and communication, Self-care, 
Mobility, Interpersonal relationships, Work and house-
hold roles and Community and civic roles. It has been 
cross-culturally tested in 16 languages in 19 different 
countries of  which Nigeria is one of  them (WHO, 
2000).
The participants interviewed are asked to indicate the 
experienced level of  difficulty (none 1, mild 2, moder-
ate 3, severe 4, extreme 5), by taking into account the 
way in which they normally perform a given activity. 
The sum score for global disability therefore ranges 
from 12 (no disability) to 60 (complete disability)
The internal consistency and test-retest reliability of  the 
overall WHODAS 2.0 is high. Scoring was done using 
a simple sum scoring method.  It has an administration 
time of  approximately 5 minutes.
Statistical analysis
Data was analyzed using the Personal Computer version 
of  Statistical Package for the Social Sciences (SPSS-PC) 
Version 15. All tests of  significance were two-tailed at 
the 5% level and confidence interval estimation at 95%.
Results
A total of  367 participants, 189 females (51.5%) and 
178 (48.5%) males were studied. The mean age of  the 
participants was 34.1 ± 9.94 (range 18-63 years). The 
majority of  the participants, 266 (72.5%), were less 
than 40 years. Most of  them, 302 (82.3%) had been ill 
for more than 3 years. Most of  the participants, 241 
(65.7%), were never married.  The majority of  the par-
ticipants, 203 (55.3%), had secondary education and 
majority were unemployed, 203 (55.3%). Almost all of  
the participants, 364 (99.2%), were Christians.
A comparison of  the socio-demographic characteristics 
of  participants with anxiety disorder and without anxi-
ety disorder (Table 1) showed that more of  the partici-
pants with anxiety disorder were females and that most 
of  them belonged to the age range 30-49 years. The 
mean age of  the 
participants with anxiety disorder was 33.82 ± 8.66 
years. There was no significant difference in the rate of  
marriage, education and employment between the two 
comparison groups.
 
Table 1:    Comparison of the socio-demographic  characteristics of  
participants with anxiety disorder and without anxiety disorder. 
 






Test statistic p-value 











Female 26 (57.8) 163 (50.6)   
 
Age (years) 
    
10-29 13 (28.9) 121 (37.6) t=-0.19 p<0.84 
30-49 29 (64.5) 167 (71.9)   
50-69 3 (6.7) 34 (10.6)   
















Not married 35 (77.8) 245 (76.1)   
 
Educational level     
No formal education 2 (4.4) 14 (4.3) ϰ²=0.00 p<0.99 
Formal education 43 (95.6) 308 (95.7)   
Employment status     
Employed 24 (53.3) 140 (43.5) ϰ²=1.51 p<0.21 
Not employed 21 (46.7) 182 (56.5)   
Table 1: Comparison of  the socio-demographic  characteristics of   participants with anxiety disorder and 
without anxiety disorder.
Forty five (12.3%) of  the participants had anxiety dis-
order. Of  all the participants studied, 6.3% had  gener-
alized anxiety disorder, 3.3%  had  obsessive  compul-
sive  disorder  while  2.7%  had phobic anxiety disorder. 
None of  the participants met the diagnosis for panic 
disorder.
More females (Table 2) had  generalized  anxiety dis-
order (κ²=4.93, p<0.03). There was no significant  as-
sociation  between  obsessive  compulsive  disorder 
(κ²=0.48,  p<0.49),  phobia (κ²=0.54, p<0.46) and gen-
der.
Table 2:  Distribution of  anxiety disorder by gender.
Variable          Type of anxiety disorder                                     n                  % of anxiety disorder
      Male
                         Generalized Anxiety Disorder                              6                   13.3
                         Obsessive Compulsive Disorder                          7                   15.6
                         Phobia                                                                  6                   13.3
      Female
                        Generalized Anxiety Disorder                    17                 37.8
                        Obsessive Compulsive Disorder                    5                 11.1
                        Phobia                                                                    4                  8.9
 
It was revealed (Table 3) that among the participants, 
more of  those with generalized anxiety disorder, 16 
(69.6%) were on high dosage of  antipsychotic com-
pared to 173 (50.3%) without generalized anxiety dis-
order (κ²=3.21, p<0.07). The participants with phobic 
anxiety disorder were significantly more likely to be on 
low dose compared to those without phobia (κ²=4.08, 
p<0.04) 







Dosage                         Anxiety disorder                              Statistics 
Yes                         No 
n (%)                     n (%) 
 
 
High dose           16 (69.6)                    173 (50.3)                ϰ²=3.21 
 
Low dose            7 (30.4)                      171 (49.7)                p<0.07
OCD 
 
High dose            6 (50)                         183 (51.5)                ϰ²=0.01 
 




High dose            2 (20)                         187 (52.4)                ϰ²=4.08 
 
Low dose             8 (80)                         170 (47.6)                p<0.04 
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The participants’ WHODAS scores were dichotomized 
(yes/no) such that participants with a total score of  12 
were regarded as having no disability while scores above 
12 indicated presence of  disability.  The participants 
with anxiety disorder had a mean WHODAS score of  
26.0 ± 7.6 compared to 21.5 ± 8.3 for those without 
anxiety disorder (t= 3.50, p<0.001).
Among the participants studied, Pearson correlation 
showed no significant correlation between WHODAS 
scores  and  dosage  of   antipsychotics  (in  chlorprom-
azine  equivalent)  among  the patients with anxiety dis-
order (r=0.22, p<0.14).
Among all the participants studied, the mean PANSS 
score was 45.01 ± 11.89 (range 30-94). The participants 
with anxiety disorder had a mean PANSS score of  50.6 
± 9.3 compared to 44.2 ± 12.0 for those without anxie-
ty disorder (t= 3.4, p< 0.001). 
 
Forty five participants had any anxiety disorder; the 
managing psychiatrist identified only 2 (4.4%). There is 
a poor level of  agreement in the rate of  identification 
of  anxiety disorders
(kappa= 0.08, p<0.001).
Table 4           Identification of anxiety disorder by managing psychiatrist 
 
 





Anxiety   disorder   identified   in 
folder 
2 (4.4)              kappa=0.08            p<0.001
 
Anxiety disorder not identified in folder 43 (95.6)
Table 5 shows the correlates of  comorbid anxiety dis- order in schizophrenia. None of  the variables was a sig-
nificant predictor of  anxiety disorder in schizophrenia.

































Employment .330 1 .200 
 
Constant 1.014 1 .024 
 
Tabl  5:  Correlates of comorbid anxiety disorder in schizophrenia.
Discussion
Different studies have reported a wide range of  prev-
alence for anxiety disorder in schizophrenia ranging 
from  30-85%7.  The   wide   variations  in  the  preva-
lence   rate  could  be   due  to methodological differenc-
es, heterogeneity among definitions of  symptoms and 
rating instruments used for diagnosis. Some of  these 
studies included patients with schizoaffective disorder 
and schizophreniform disorders and it was difficult to 
do a direct comparison because the two groups were 
not analyzed separately.
In this study, a 12.3% prevalence rate of  anxiety disor-
der was found which is comparable to 15% comorbidity 
rate for anxiety disorders in patients with non-affective 
psychosis which included schizophrenia and schizo-
phreniform disorders reported in a previous study24.  A 
previous work that  studied racial  disparity in  the  rate 
of   diagnosis  of   anxiety disorder  in  Caucasians and 
African-Americans  with  schizophrenia  reported  27% 
anxiety  disorder  diagnosis  rate  in Caucasians and 13% 
in African Americans which they attributed to under-re-
porting of  anxiety symptoms in African-Americans9. 
However it is possible that the difference may be due to 
racial differences in the  rate of   anxiety experienced by 
the  two groups. Other  studies  of   anxiety disorder in 
schizophrenia reported a higher anxiety rate of  43%23 
and 41.5%22. These higher rates may be explained by 
the use of  in-patients who may report higher rates of  
anxiety than the out- patients23 and the measurement 
of  lifetime rates instead of  current rate of  anxiety dis-
order11.
Differences  in  the  rates  of    compulsive  disorder13, 
14,23,25,26,  phobic  anxiety disorder8 and panic disorder11,23 
reported elsewhere and rates revealed in this study may 
be due to methodological differences. 
 
Participants with co-morbid anxiety disorder had sig-
nificantly more disability than those without co-morbid 
anxiety. This may be due to additional burden imposed 
by anxiety symptoms on a person with schizophrenia. 
This agrees with what was reported in a previous study 
which found significantly higher scores in global scale, 
work subscale, and social life subscale of  the Sheehan
Disability  Scale  in  schizophrenia  subjects  with  co-
morbid  anxiety17,11,27.  This  is  also  in agreement with 
other studies that found that co-morbid anxiety in 
schizophrenia was associated with significantly lower 
level of  function28,29.
The participants in this study who had anxiety disor-
der had a significantly higher mean PANSS score than 
those without anxiety disorder. A study carried out in 
Israel reported higher total PANSS score in in-patients 
with schizophrenia who also had co-morbid anxiety20. 
This may imply that the presence of  anxiety disorder in 
schizophrenia is a poor prognostic indicator.
There was a low rate of  identification of  anxiety dis-
order in the participants by the managing psychiatrists 
which agrees with a previous Australian study that re-
ported virtually no recognition of  anxiety disorder in 
patients with schizophrenia by the clinicians30. The low 
rate of  recognition may be due to more attention being 
paid to florid psychotic symptoms or the clinicians’ in-
ability to recognize the symptoms of  anxiety in these 
patients.
Among the participants, there was an increased rate of  
generalized anxiety disorder in the females. This agrees 
with previous studies that report generalized anxiety 
disorder to be twice as common in females31.
 
Conclusion 
This study highlights the fact that anxiety disorders are 
common in patients with schizophrenia and are poorly 
recognized by psychiatrists. Given that anxiety disor-
ders contribute to significant disability in patients with 




The results of  this study should be interpreted with 
caution because of  several methodological shortcom-
ings. First, it was cross-sectional in nature, thus the 
causality of  relationships between smoking and demo-
graphic and clinical variables could not be explored. 
Second, it was a cross- sectional non-population repre-
sentative study. Its results cannot be generalized to the 
entire population. Despite these caveats, findings from 
this study should serve as a baseline data for compari-
son in future.
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